Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). In Finland, the market for these drugs is developing in response to various factors.
Customer preferences: Finland has a high prevalence of respiratory diseases, which drives demand for bronchodilator drugs. Patients prefer drugs that provide quick relief and have minimal side effects. As a result, there is a growing demand for combination drugs that offer both bronchodilator and anti-inflammatory effects. Patients also prefer inhalers over other forms of medication as they are easy to use and provide targeted delivery of the drug.
Trends in the market: The market for bronchodilator drugs in Finland is expected to grow due to the aging population and increasing prevalence of respiratory diseases. There is also a trend towards personalized medicine, where drugs are tailored to an individual's genetic makeup and disease profile. This trend is likely to drive the development of new drugs and treatment options in the market.
Local special circumstances: Finland has a well-developed healthcare system that provides universal coverage to its citizens. The government regulates drug prices, which can limit the profitability of pharmaceutical companies. However, Finland has a high level of healthcare spending per capita, which creates opportunities for drug manufacturers to sell their products. The country also has a strong pharmaceutical industry, which contributes to the development of new drugs and treatment options.
Underlying macroeconomic factors: Finland has a highly educated population and a strong economy. The country has a high level of research and development spending, which contributes to the development of new drugs. Finland is also a member of the European Union, which provides access to a large market for pharmaceutical companies. However, the country has a relatively small population, which can limit the potential market size for new drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
